The significance of the work lies in a deceptively simple question that has rarely been asked: does the handedness of a nanoparticle’s atomic architecture, not just its surface chemistry, change how cells respond to it? Most chiral nanomaterials studied to date achieve their handedness by decorating otherwise symmetrical particles with chiral surface ligands. That approach works, but it carries risks, because loosely attached ligands can detach in the body, triggering toxicity or immune reactions. The new study took a different route. Using a seeded growth method, the researchers introduced either L- or D-cysteine as a chiral inducer while gold atoms deposited onto pre-formed seed crystals, coaxing the entire nanoparticle into a stable, mirror-image geometry that cannot shed its chirality because the chirality is baked into the crystal itself.

To disentangle the effects of handedness from those of particle shape, the team ran a complete two-by-two factorial experiment. They prepared gold nanoparticles in two distinct morphologies, multifaceted rhombi cuboctahedra and simple cubes, each grown with D-, L-, or racemic DL-chirality. Circular dichroism spectroscopy confirmed that the D- and L-versions produced near-perfect mirror-image optical signatures, with characteristic peaks near 600 nanometers for the rhombi cuboctahedra and around 650 nanometers for the cubes, while the racemic particles showed no chiral signal at all. Scanning electron microscopy revealed the left- and right-handed orientations of individual particles, and dynamic light scattering placed all variants in the 150 to 180 nanometer range, a size window known to favor endocytic uptake, which helped rule out size as a confounding variable.

With the particle library in hand, the researchers grafted on a minimal surface coating of methoxypolyethylene glycol thiol to confer water solubility and colloidal stability, then attached siRNA through robust gold-sulfur covalent bonds. Crucially, this gentle modification left the intrinsic chiroptical signatures intact, and the signals remained stable over a full week of monitoring. Energy-dispersive X-ray analysis found no detectable residues of the cationic surfactant used during synthesis, addressing a common toxicity concern. When free siRNA and nanoparticle-bound siRNA were incubated in serum, gel electrophoresis showed that the bound cargo remained undegraded, confirming that the gold scaffold shields its fragile payload from the nucleases that would otherwise destroy it within hours.

The first hint that handedness truly matters came from quantitative binding measurements. Using microscale thermophoresis, the team determined that D-handed rhombi cuboctahedra grip siRNA with a dissociation constant of about 0.099 micromolar, roughly 1.4-fold tighter than their L-handed twins. That modest difference in affinity proved to be a harbinger of much larger functional gaps downstream. In GFP-expressing lung cancer cells, the right-handed particles silenced the reporter gene far more effectively than their left-handed or racemic counterparts, and the rhombi cuboctahedral shape consistently outperformed the cube. The winning combination, D-handed rhombi cuboctahedra, achieved a GFP silencing efficiency of 71.1 percent, nearly 1.5 times the 48.2 percent delivered by the same right-handed chirality on a cubic scaffold.

To understand why mirror-image particles behave so differently, the researchers turned to high-throughput proteomics. Cells treated with siRNA-free D-, L-, or DL-particles showed clearly segregated protein expression profiles, with fifty proteins significantly differentially expressed between the D- and L-treatment groups. The affected pathways spanned endoplasmic reticulum function, membrane-bound organelles, cell adhesion, proteostasis, and transcriptional regulation, painting a picture in which the handedness of an inorganic crystal can reshape fundamental aspects of cellular machinery. The authors suggest that this chirality-specific proteome remodeling underlies the divergent uptake and trafficking behavior, engaging pro-endocytic machinery in some cases while leaving negative regulatory pathways untouched, though the precise membrane protein partners remain to be fully mapped.

Having identified the optimal carrier, the team loaded it with siRNA targeting PD-L1, the immune checkpoint molecule that many tumors overexpress to cloak themselves from immune attack. In H460 non-small cell lung cancer cells and A549 lung adenocarcinoma cells, the D-handed rhombi cuboctahedral formulation cut cell viability to roughly 20 to 40 percent at modest doses, while left-handed and racemic versions were far less potent. EdU proliferation assays and colony formation experiments confirmed the hierarchy, and control experiments with blank vectors, scrambled siRNA, and free siPD-L1 showed no significant inhibition, demonstrating that the effect flowed from genuine, carrier-protected gene delivery rather than nonspecific toxicity. Quantitative PCR revealed that the lead formulation knocked down PD-L1 mRNA by about 60 percent and STAT3 mRNA by about 55 percent in H460 cells, with immunofluorescence confirming a matching drop in PD-L1 protein.

Intriguingly, the silencing did not trigger the classical apoptotic executioner caspase-3, and Annexin V staining detected no significant apoptotic signal, suggesting the tumor cells succumb through non-apoptotic routes such as cell cycle arrest or senescence. The therapeutic effect also scaled with each cell line’s baseline PD-L1 expression, hinting that PD-L1 levels could serve as a biomarker to guide patient selection. In mice bearing subcutaneous H460 tumors, intratumoral injection of the D-handed formulation over twelve days markedly suppressed tumor growth and weight compared with all other groups, while body weights remained stable. Serum chemistry showed normal liver and kidney markers, mass spectrometry found no significant gold accumulation in major organs, and histological examination of heart, liver, spleen, lung, and kidney revealed no pathological abnormalities. In tumor tissue itself, PD-L1 staining dropped sharply and the proliferation marker Ki67 fell from roughly 60 percent to about 20 percent of tumor cells.

The study’s broader message is that chirality deserves a seat at the table as a fundamental design parameter for nanomedicine, on par with size, shape, and surface charge, and that intrinsic crystallographic handedness offers a durable, ligand-free way to exploit it. Because the chiral advantage emerges from the particle’s own geometry, the platform sidesteps the immunogenicity and instability that plague detachable targeting ligands, a meaningful step toward clinical translation. The authors are careful to note the limits of the current work: delivery was performed by local intratumoral injection, and systemic, intravenous delivery, the ultimate goal for treating metastatic disease, remains to be demonstrated. Even so, the demonstration that a simple change in mirror-image geometry can nearly double gene-silencing efficiency opens a striking new avenue for precision cancer therapy, one in which the handedness of matter itself becomes a therapeutic instrument.

Subject of Research: Chirality- and morphology-dependent siRNA delivery using intrinsically chiral gold nanoparticles for targeted lung cancer therapy

Article Title: Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles

Article References: Li, Q., Xu, J., Zhang, E., Liu, C., Liu, W., Yan, K., Xu, D., & Wang, J. (2026). Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles. Materials Today Bio, 41, Article 103745. https://doi.org/10.1016/j.mtbio.2026.103745

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103745

Keywords: siRNA delivery, chiral gold nanoparticles, PD-L1, lung cancer, nanomedicine, chirality, gene silencing, RNA interference, drug delivery, proteomics, tumor therapy, Materials Today Bio

Organoid technology has reshaped regenerative medicine by moving beyond flat cell culture toward self-organized three-dimensional microtissues that better reproduce native tissue architecture and function. Unlike conventional two-dimensional cultures, bone organoids preserve cell-cell communication, cell-matrix interactions, lineage patterning, and extracellular matrix remodeling within a spatially relevant environment. Recent years have seen skeletal organoid systems expand to include bone marrow-like, trabecular-like, callus-like, and woven-bone-like constructs, with matrix engineering and biofabrication enabling tighter control of geometry and maturation. Yet the field still confronts key barriers, including inadequate vascularization, immature mechanics, diffusion limitations in larger constructs, and the absence of standardized bioactive programming. In this study, the term bone organoids refers specifically to bone marrow stromal cell-derived three-dimensional osteogenic microtissues that reproduce selected features of bone formation, including cell-cell interaction, matrix production, and mineral deposition, rather than fully vascularized or marrow-containing bone equivalents.

Achyranthes bidentata, the botanical source of a traditional Chinese medicine, emerged as an attractive candidate for biofunctionalizing such constructs. Pharmacognostic studies identify multiple bioactive constituents in the plant, including polysaccharides, saponins, steroids, and related small molecules, and toxicology work suggests a favorable safety profile at therapeutic doses. Experimental evidence supports a direct role in skeletal repair: AB saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK/MAPK pathway, osteoblast studies show enhanced proliferation and Runx2-associated osteogenic activity after treatment, and purified polysaccharide fractions exhibit in vitro osteogenic activity. In parallel, AB regulates the resorptive arm of bone remodeling, with prior studies demonstrating suppression of osteoclastogenesis through inhibition of RANKL signaling and osteoprotective effects in vivo through regulation of the RANKL/RANK/OPG axis. This dual anabolic and anti-resorptive potential is precisely the type of combined cue needed for functional bone regeneration, yet until now AB research and organoid engineering had largely progressed in parallel.

The research team, led by Chenxing Lu and colleagues, designed a four-stage workflow: dose screening of AB in rat bone marrow-derived mesenchymal stromal cells, generation and characterization of AB-bone organoids, evaluation in a critical-sized calvarial defect model, and an exploratory retrospective clinical analysis of AB exposure in tibial fracture healing. The botanical material was authenticated by macroscopic and microscopic examination according to the Pharmacopoeia of the People’s Republic of China, with voucher specimens deposited at the Institute of Chinese Materia Medica. Dried roots were decocted with distilled water, filtered, concentrated, and lyophilized to an 18.5 percent extraction yield, then characterized by high-performance liquid chromatography fingerprinting to establish batch traceability before any biological testing began.

Dose screening revealed a concentration-dependent osteopromotive window. Bone marrow stromal cells exposed to graded concentrations from 0 to 400 micrograms per milliliter showed good cytocompatibility at low and intermediate doses, with cell viability and proliferative activity rising steadily up to 200 micrograms per milliliter, the concentration that produced peak alkaline phosphatase activity and Alizarin Red S-detected mineralization. At 400 micrograms per milliliter, the proliferative benefit was attenuated, indicating that the effect was concentration dependent rather than linearly cumulative. Quantitative PCR confirmed that AB markedly upregulated the osteogenic program, increasing expression of Col1a1, Runx2, Opn, and Ocn. Mechanistic experiments using PD98059, a selective ERK/MAPK pathway inhibitor, showed that AB increased ERK1/2 phosphorylation and that blocking the pathway partially attenuated AB-enhanced alkaline phosphatase activity and mineralized matrix formation, implicating ERK/MAPK signaling as a partial, though not exclusive, contributor to the herb’s pro-osteogenic effect.

The pivotal step came when the team incorporated AB into bone organoid culture. Single-cell suspensions of stromal cells were seeded into ultra-low-attachment plates to form compact spheroids over three days, then embedded in growth factor-reduced Matrigel and cultured in osteogenic medium for 28 days, with 200 micrograms per milliliter AB added throughout maturation. Live/dead staining showed both groups remained viable, but AB-treated organoids displayed more widespread calcein-AM signal and reduced propidium iodide incorporation. Quantitative analysis demonstrated that AB-treated organoids achieved a larger cross-sectional area, suggesting accelerated tissue assembly and volumetric growth. Histological and matrix analyses confirmed the functional differences: AB-bone organoids exhibited stronger Alizarin Red S, alkaline phosphatase, and collagen type I staining, indicating enhanced calcium deposition, osteogenic enzyme activity, and extracellular matrix production, while immunofluorescence revealed more organized F-actin architecture and stronger Runx2 expression consistent with heightened osteogenic lineage activation.

Head-to-head comparison of monolayer cultures, untreated bone organoids, and AB-bone organoids revealed a stepwise enhancement in osteogenic output, with AB-bone organoids achieving the highest levels of enzymatic activity and matrix mineralization, accompanied by increased protein expression of COL-I, Runx2, and OPN and higher viability. The decisive test, however, came in vivo. In a critical-sized 5-millimeter calvarial defect model in adult rats, animals receiving AB-bone organoids showed more extensive defect bridging and denser mineralized tissue on micro-CT reconstructions at 12 weeks than those receiving untreated organoids or no implant. Quantitative analysis confirmed the most favorable bone microarchitecture in the AB-bone organoid group, with increased bone volume fraction, bone mineral density, trabecular thickness, and trabecular number, together with reduced trabecular separation. Histology showed greater bone fill and more organized collagen deposition, and immunohistochemistry revealed more abundant COL-I, OPN, and OCN-positive matrix within the regenerative area.

To explore clinical relevance, the team conducted a retrospective cohort study at Taizhou Hospital of Traditional Chinese Medicine, screening 126 consecutive tibial fracture patients operated on between January 2022 and December 2024, of whom 40 met eligibility criteria and were divided into 20 receiving oral AB beginning one month after surgery for six weeks and 20 receiving standard care. Baseline characteristics were well balanced between groups. Postoperative AB administration was associated with substantially shorter mean radiographic healing time of 3.8 versus 4.9 months, higher modified Radiographic Union Scale scores at final follow-up of 14.1 versus 12.3, lower pain scores of 1.3 versus 2.6 on the visual analogue scale, and superior lower-extremity function scores of 72.5 versus 65.2. Serial radiographs showed earlier callus formation and advanced remodeling in AB-treated patients, although the proportion achieving union by six months did not differ significantly.

The authors are careful to delineate the boundaries of these findings. The animal experiment evaluated localized implantation of AB-preconditioned organoids, while the clinical cohort evaluated systemic oral administration with entirely different pharmacokinetics, so the human data provide only indirect, hypothesis-generating support rather than evidence for the clinical feasibility of organoid implantation. Retrospective design cannot fully account for unmeasured confounding, and factors such as fracture severity, fixation characteristics, and rehabilitation compliance were not uniformly available. The calvarial model is non-load-bearing, vascularization was not directly quantified, the specific bioactive constituents responsible remain unidentified, and the ERK/MAPK experiments were conducted only in monolayer cells. Even so, the conceptual advance is considerable: a traditional osteoactive botanical factor has been repurposed as a developmental instruction for bone organoids, upgrading the therapeutic unit from isolated cells or soluble factors to an implantable living osteogenic microtissue, and defining a promising direction for biologically instructed bone regeneration that now awaits testing in load-bearing models, vascularized constructs, and eventually dedicated clinical trials.

Subject of Research: Achyranthes bidentata-functionalized bone marrow stromal cell-derived bone organoids for enhanced bone defect repair

Article Title: Achyranthes bidentata –functionalized bone organoids enhance bone defect repair

Article References: Lu, C., Qin, X., Lin, Z., Han, S., Ding, P., Xu, L., Zheng, X., Hu, B., Chen, F., & Wu, D. (2026). Achyranthes bidentata–functionalized bone organoids enhance bone defect repair. Materials Today Bio, 41, Article 103716. https://doi.org/10.1016/j.mtbio.2026.103716

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103716

Keywords: bone organoids, Achyranthes bidentata, bone regeneration, critical-sized defects, mesenchymal stromal cells, ERK/MAPK signaling, traditional Chinese medicine, calvarial defect model, fracture healing, osteogenesis, tissue engineering, Materials Today Bio

The heart of the technology is deceptively small: spherical nanoparticles roughly 30 nanometers across, each built around a core of iron oxide wrapped in a protective silica shell. This architecture gives the particles two crucial properties at once. The iron oxide core makes them strongly magnetic, allowing them to be maneuvered and concentrated within a sample without the lengthy centrifugation steps that conventional immunoassays demand, while the silica shell provides a chemically stable surface onto which the researchers attach thousands of molecular structures that mimic the antigenic determinants of beta-lactam antibiotics. Ezequiel Pérez-Inestrosa, Professor of Organic Chemistry at the University of Malaga and one of the study’s authors, describes each particle as acting ‘like a tiny magnet covered with thousands of molecular hooks.’ If a patient’s blood contains IgE antibodies responsible for the allergy, those antibodies are captured far more readily than with existing methods.

The significance of that capture efficiency becomes clear when the immunology of drug allergy is considered. IgE antibodies are extraordinarily scarce in the bloodstream, and the allergic response to penicillins is directed against haptens, small chemical fragments that only become immunologically visible when they are covalently bound to carrier proteins in the body. Recreating these hapten-carrier complexes faithfully on a solid support is a formidable synthetic chemistry challenge, and it is precisely where the Malaga team’s organic chemistry expertise proves decisive. By presenting a dense, well-defined array of antibiotic-derived structures on the nanoparticle surface, the platform maximizes the probability that even low-abundance, clinically relevant IgE molecules will bind, and the magnetic separation then allows those bound antibodies to be isolated and measured cleanly against a low background of noise.

Performance in the laboratory translated directly into diagnostic accuracy. In the study, the researchers analyzed blood samples from nearly one hundred people: 50 patients with confirmed amoxicillin allergy and 44 individuals who tolerated these antibiotics without incident. The system detected virtually all true cases of allergy while substantially reducing both false negatives and false positives, according to María José Torres, Professor of Medicine and one of the study’s lead researchers. The platform was benchmarked against two established techniques, ImmunoCAP, the most widely used commercial test, and the conventional radioallergosorbent test known as RAST. The gap in sensitivity, particularly for amoxicillin, was stark. Where the nanoparticle platform flagged 98 percent of confirmed allergic patients, ImmunoCAP managed only around 17 percent, a shortfall that means the majority of genuinely allergic individuals have historically received negative results that offer false reassurance.

The stakes of getting these diagnoses right are far higher than they might first appear. Penicillin allergy is dramatically overdiagnosed. Although between 8 and 25 percent of the population report being allergic to these antibiotics, only between 1 and 10 percent actually are. That gap between perception and reality leaves millions of people carrying an incorrect label in their medical records, and the consequences cascade through their subsequent care. Patients mislabeled as penicillin-allergic are treated with alternative drugs that are generally less effective and more toxic, and the substitution contributes to the emergence of bacterial resistance, one of the most pressing threats in modern medicine. ‘This incorrect label leads to the use of alternative drugs that are generally less effective, more toxic and contribute to the emergence of bacterial resistance,’ Pérez-Inestrosa explains. He stresses that identifying these cases safely would make it possible to remove thousands of incorrect diagnoses that currently shape and constrain patients’ treatment.

Beyond accuracy, the new platform promises to make the diagnostic journey itself safer and simpler. The definitive test for drug allergy has long been the drug provocation test, in which the patient is deliberately given the suspected medication under close medical supervision. It is informative, but it carries genuine risks, including the possibility of triggering a severe systemic reaction, and it requires specialist settings and considerable time. The nanoparticle-based assay, by contrast, can be performed rapidly in the laboratory on a simple blood sample, without exposing the patient to the drug at all and without the lengthy centrifugation procedures that slow down conventional workflows. A reliable in vitro alternative of this kind could allow clinicians to triage patients efficiently, reserving provocation testing only for cases where it is truly necessary.

The study is also a showcase for collaborative, translational science. Alongside the University of Malaga’s Department of Organic Chemistry, where Yolanda Vida and María I. Montañez serve as the study’s lead authors, the work drew on the IBIMA BIONAD Platform, the Inflammatory Diseases Network (REI) and the Regional University Hospital of Malaga, combining synthetic chemistry, materials science, immunology and clinical allergy expertise in a single program. That breadth matters, because a diagnostic technology that lives or dies on the precision of surface chemistry must ultimately prove itself against the messy, variable reality of patient sera, and few single laboratories possess the full range of skills needed to close that loop.

The implications, if the technology survives the scrutiny that now follows, extend beyond the penicillins. Beta-lactams are the world’s most prescribed class of antibiotics, and reliable, rapid allergy diagnosis would unlock first-line therapy for the vast majority of people currently denied it. There are also immediate operational benefits: shorter laboratory turnaround, reduced reliance on radioisotope-based legacy assays such as RAST, and the potential for standardization across centers because the magnetic separation is straightforward to automate. The authors themselves, however, are careful about the pace of translation. In light of their findings, they emphasize the need for further, larger multicentre studies and formal clinical validation before the platform can be introduced into hospitals and used routinely, a prudent stance given that diagnostic tests must perform consistently across diverse populations and instrumentation.

Still, the trajectory of this work is a reminder of how materials science quietly reshapes clinical medicine. Thirty-nanometer spheres of iron oxide and silica, decorated with molecular hooks synthesized by organic chemists, have turned a notoriously unreliable diagnostic corner into something that approaches certainty. For the millions of patients whose misplaced allergy label steers them toward inferior antibiotics, and for the clinicians trying to reconcile a 98 percent sensitivity figure with the 17 percent of the status quo, that tiny magnetic scaffold may prove to be one of the most consequential pieces of chemistry in the allergy clinic in years. The University of Malaga team’s findings, published in Materials Today Bio, mark the point at which magnetic nanoparticles moved from the bench toward a clinically relevant role in the diagnosis of beta-lactam allergy.

Subject of Research: Magnetic nanoparticle-based in vitro diagnosis of allergy to beta-lactam antibiotics such as amoxicillin and other penicillins

Article Title: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins

Article References: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: magnetic nanoparticles, penicillin allergy, amoxicillin, beta-lactam antibiotics, IgE antibodies, in vitro diagnostics, ImmunoCAP, drug provocation test, antibiotic resistance, University of Malaga, Materials Today Bio, allergy diagnosis